File(s) not publicly available

Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

journal contribution

posted on 2023-01-27, 05:17 authored by Feby SaviraFeby Savira, B H Wang, A R Kompa, Z Ademi, A Owen, A Tonkin, S Zoungas, D Liew, E Zomer

Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective

History

Journal

EUROPEAN HEART JOURNAL

Volume

41

Pagination

1051 - 1051

Location

ELECTR NETWORK

Start date

2020-08-29

End date

2020-09-01

ISSN

0195-668X

eISSN

1522-9645

Language

English

Author URL

https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606106301054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a045e4b2bb1f2b747c68c720ec8913b7

Usage metrics

Research Publications

Categories

Uncategorized

Keywords

Science & Technology Life Sciences & Biomedicine Cardiac & Cardiovascular Systems Cardiovascular System & Cardiology Dapagliflozin cost-effectiveness heart failure hospitalisation incremental cost-effectiveness ratio

Licence

All Rights Reserved

Exports